Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inovio Pharmaceuticals Inc (INO), Alnylam Pharmaceuticals, Inc. (ALNY): This Week in Biotech

With the SPDR S&P Biotech Index up 33% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

It was an unmistakably good week for biotechnology stocks with everything from new drug filings, to clinical data and buyout rumors fueling much of the sector higher.

Biotechnology juggernaut Pharmacyclics, Inc. (NASDAQ:PCYC) — a company that has returned close to 19,000% since its recession lows — ignited investor optimism when it and licensing partner Johnson & Johnson (NYSE:JNJ) filed a new drug application for ibrutinib. This is truly exciting news, because it marks the first breakthrough therapy drug that’s filed for an NDA, and will act the test subject to the rest of the breakthrough therapy designated drugs. Ibrutinib delivered exceptional results in chronic lymphocytic leukemia and mantle cell lymphoma in terms of overall response rate, which should probably net it an approval from the Food and Drug Administration.

On the clinical data front, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Inovio Pharmaceuticals Inc (NYSEMKT:INO) both put investors in their happy place.

For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) this was the second consecutive week that it reported positive clinical results. In this week’s data, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported positive top-line results for ALN-TTRsc, an early stage subcuteanous RNA interference therapeutic designed to treat familial amyloidotic cardiomyopathy. In the trial, ALN-TTRsc reduced serum TTR levels by greater than 80% in treated patients. If you recall, the company is also developing ALN-TTR02, an intravenous treatment for familial amyloidotic polyneuropathy that reduced serum TTR levels by 93% in a mid-stage trial. Together, these two TTR-mediated amyloidosis diseases affect 50,000 people worldwide and could kick-start Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s pipeline.

In the case of the much smaller Inovio Pharmaceuticals Inc (NYSEMKT:INO), shareholders were treated to a double dose of good news. On Monday, Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported that its universal H7N9 DNA vaccine protected 100% of vaccinated animals in trials from the H7N9 virus. Then, on Wednesday, Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported that its next-generation HIV vaccine when combined with its cellectra electroporation delivery technology increased the response of CD8 T-cells from 7% to 52%! While there’s plenty to be excited about for Inovio Pharmaceuticals Inc (NYSEMKT:INO) shareholders, I’d certainly urge some caution as it’s delivered nothing but consistent losses over the past 30 years and will face a lot of competition in H7N9 vaccines.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.